Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Slayback Pharma logo — Slayback Pharma believe every pharmaceutical product exhibit...

Slayback Pharma

Slayback Pharma believe every pharmaceutical product exhibits its own unique personality

Founded 2011 United States Princeton, United States 41 employees Acquired Total: $110.00M Biopharma, Manufacturing +1

General Information

Company Name Slayback Pharma
Founded Year 2011
Location United States Princeton, United States
Founders / Decision Makers
Team member Team member
Employees 41
Industries Biopharma, Manufacturing, Pharmaceutical
Funding Stage Acquired
Business Model B2B
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Slayback Pharma. To contact Slayback Pharma, visit slayback-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Slayback Pharma compare?

A PDF of Slayback Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Slayback Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Slayback Pharma

Slayback Pharma, founded in 2011, is a specialty pharmaceutical company based in the United States. They focus on developing and manufacturing complex generic pharmaceutical products, placing significant emphasis on complex injectables and non-solid oral products. Their portfolio stands out through strategic product selection and execution, supported by a network of contract R&D laboratories and manufacturing organizations.

By leveraging sophisticated manufacturing and innovative drug delivery technologies, Slayback Pharma has successfully established a unique presence in the Biopharma, Manufacturing, and Pharmaceutical industries. Their distinctive approach is summarized by their slogan: "Slayback Pharma believes every pharmaceutical product exhibits its own unique personality."

The company's growth trajectory witnessed a significant boost with a $50.00M Series B investment from Everstone Capital on 06 January 2020. This funding underscores investor confidence in Slayback Pharma's innovative capabilities and market potential.

Business keywords: Complex Generics, Specialty Pharmaceuticals, Complex Injectables, Non-Solid Oral Products, Drug Delivery Technologies, Contract R&D, Manufacturing Network, Sterile Formulations, Nano-spheres, Oil-in-Water Emulsions, Hormonal Products, Cross-Contamination Control, Cost-Reduction in Therapy, Value Proposition Development, Innovative Drug Development

Services & Products

Development of Pharmaceuticals
Marketing and Sales
Patient Direct Solutions
Patient Support Programs
Educational Grant Applications

Target Customers

Overlooked Patients Patients with Chronic Diseases Healthcare Providers Pharmacists

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition Undisclosed 1
Azurity Pharmaceuticals
01 Sep 2023
Series B $50.00M 1
Everstone Capital
Everstone Capital
01 Jan 2020
Early VC $60.00M 1
KKR
KKR
01 Jan 2017

Slayback Pharma Alternatives & Competitors

View All Alternatives
Slayback Pharma vs
Celadon Pharmaceuticals
Celadon Pharmaceuticals United Kingdom

UK-based pharmaceutical company focused on R&D, cultivation, production and sale of cannabis-based m...

IPO
18 employees
Biopharma, Biotechnology
Compare Slayback Pharma vs Celadon Pharmaceuticals
Slayback Pharma vs
Anodyne Nanotech, Inc
Anodyne Nanotech, Inc United States

Simplifying Chronic Care

20 employees
Biopharma, Biotechnology
Compare Slayback Pharma vs Anodyne Nanotech, Inc
Slayback Pharma vs
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. United States

Revolutionizing treatment for severe allergic reactions with the development of a needle-free epinep...

Merged
171 employees
Biopharma, Health Care
View all alternatives

FAQ About Slayback Pharma

Slayback Pharma believe every pharmaceutical product exhibits its own unique personality
Slayback Pharma was founded in 2011.
Slayback Pharma is headquartered in Princeton, United States.
Slayback Pharma operates in Biopharma, Manufacturing and Pharmaceutical. Its work centres on Complex Generics, Specialty Pharmaceuticals, Complex Injectables and Non-Solid Oral Products. Its customers include Overlooked Patients, Patients with Chronic Diseases and Healthcare Providers.
Slayback Pharma has a B2B business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Slayback Pharma has approximately 41 employees.
Slayback Pharma has completed 3 funding rounds, raising a total of $110.00M. The latest funding stage is Acquired.
Slayback Pharma offers: Development of Pharmaceuticals, Marketing and Sales, Patient Direct Solutions, Patient Support Programs, Educational Grant Applications.
Top alternatives and competitors to Slayback Pharma include Celadon Pharmaceuticals, Anodyne Nanotech, Inc, ARS Pharmaceuticals, Inc., Lumos Pharma, Drossapharm. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Slayback Pharma and Celadon Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Slayback Pharma, https://bouncewatch.com/company/slayback-pharma, updated 10 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout